Experience of application of eculizumab the child with atypical haemolytic uraemic syndrome
Abstract
Аtypical hemolytic uremic syndrome (aHUS) - genetically progressive disease with a very high risk of sudden death and irreversible and debilitating damage to vital organs. In the basis of aHUS is thrombotic microangiopathy associated with uncontrolled activation of the complement system. A new therapeutic option in the world today has been the use of monoclonal antibodies - inhibitors of the complement system (complement component C5 blocker). The only representative of this group is the drug eculizumab. In the article presented their own experience of eculizumab the child with aHUS.
About the Authors
T. P. Makarova
Казанский государственный медицинский университет ; Детская Республиканская клиническая больница Министерства здравоохранения Республики Татарстан
Russian Federation
Russian Federation
G. R. Davletbaeva
Казанский государственный медицинский университет ; Детская Республиканская клиническая больница Министерства здравоохранения Республики Татарстан
Russian Federation
Russian Federation
L. V. Poladova
Казанский государственный медицинский университет ; Детская Республиканская клиническая больница Министерства здравоохранения Республики Татарстан
Russian Federation
Russian Federation
N. V. Osipova
Казанский государственный медицинский университет ; Детская Республиканская клиническая больница Министерства здравоохранения Республики Татарстан
Russian Federation
Russian Federation
Yu. S. Melnikova
Казанский государственный медицинский университет ; Детская Республиканская клиническая больница Министерства здравоохранения Республики Татарстан
Russian Federation
Russian Federation
References
1. Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical Hemolytic-Uremic Syndrome. N Engl J Med 2009;361:345-357
2. Rodrigues de Cordoba SR, de Jorge EG.Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 2008;151:1-13
3. Kajander T, Lehtinen MJ, Hyvarinen S et al. Dual interaction of factor H with C3d and glycosaminoglycans in host non host discrimination by complement. ProcNatlAcadSci USA 2011;108:2897-2902
4. Morgan HP, Schmidt CQ, Guariento M et al. Structural basis for engagement by complement factor H of C3b on a self surface. Nat StructMolBiol 2011;18:463-470
5. Kavanagh D, Richards A, Atkinson J. Complement regulatory genes and haemolytic uremic syndromes. Annu Rev Med 2008; 59:293-309
6. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058-1066
7. Попа АВ, Лифшиц ВИ, Эмирова ХМ идр. Современные представления об атипичном гемолитико-уремическом синдроме (NON-Stx-HUS). Педиатрия 2011; 90(4): 134-140
8. Макарова ТП, Эмирова ХМ, Зверев ДВ и др. Атипичный гемолитико-уремический синдром у детей. Практическая медицина 2012; 7(62): 57-61
9. Cameron JS, Vick R. Letter: Plasma-C3 in haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Lancet 1973; 2:975
10. Ш. Луара, В. Фремю-Бачи. Атипичный гемолитико-уремический синдром. Нефрология 2012;16(2):16-48
11. Шанталь Луара. Гемолитико-уремический синдром. В: Детская нефрология, ред. Э. Лойман, А.Н. Цыгин, А.А. Саркисян. Литтерра, М., 2010:184-193
12. Pichette V, Querin S, Schurch W et al. Familial hemolytic-uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 1994; 24: 936-941
13. Bolton Maggs Paula HB. Recent advances in diagnosis and treatment of atypical haemolytic uraemic syndrome. F 1000 Med. Reports.2010; 2: 73
14. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome. Pediatr Nephrol 2008;23:1957-1972
15. Ariceta G, Besbas N, Johnson S et al. Guidelines for the investigation and initial therapy of diarrhea negative haemolytic uraemic syndrome. Pediatr Nephrol 2009;24:687-696
16. Taylor CM, Machin S, Wigmore SJ, Goodship TH. Clinical Practice Guidelines for the management of atypical Haemolytic Uraemic Syndrome in the United Kingdom. Br J Haema-tol2010;148:37-47
Review
For citations:
Makarova T.P., Davletbaeva G.R., Poladova L.V., Osipova N.V., Melnikova Yu.S. Experience of application of eculizumab the child with atypical haemolytic uraemic syndrome. Nephrology (Saint-Petersburg). 2014;18(3):84-88. (In Russ.)
Views:
721
Email this article 